252 related articles for article (PubMed ID: 15894569)
1. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure.
Karram T; Abbasi A; Keidar S; Golomb E; Hochberg I; Winaver J; Hoffman A; Abassi Z
Am J Physiol Heart Circ Physiol; 2005 Oct; 289(4):H1351-8. PubMed ID: 15894569
[TBL] [Abstract][Full Text] [Related]
2. Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Takeda Y; Zhu A; Yoneda T; Usukura M; Takata H; Yamagishi M
Am J Hypertens; 2007 Oct; 20(10):1119-24. PubMed ID: 17903697
[TBL] [Abstract][Full Text] [Related]
3. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
Brodsky S; Gurbanov K; Abassi Z; Hoffman A; Ruffolo RR; Feuerstein GZ; Winaver J
Hypertension; 1998 Oct; 32(4):746-52. PubMed ID: 9774374
[TBL] [Abstract][Full Text] [Related]
4. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients.
Keidar S; Gamliel-Lazarovich A; Kaplan M; Pavlotzky E; Hamoud S; Hayek T; Karry R; Abassi Z
Circ Res; 2005 Oct; 97(9):946-53. PubMed ID: 16179584
[TBL] [Abstract][Full Text] [Related]
5. Both aldosterone and spironolactone can modulate the intracellular ACE/ANG II/AT1 and ACE2/ANG (1-7)/MAS receptor axes in human mesangial cells.
Stoll D; Yokota R; Sanches Aragão D; Casarini DE
Physiol Rep; 2019 Jun; 7(11):e14105. PubMed ID: 31165585
[TBL] [Abstract][Full Text] [Related]
6. Genetic variation in angiotensin-converting enzyme does not prevent development of cardiac hypertrophy or upregulation of angiotensin II in response to aortocaval fistula.
Perry GJ; Mori T; Wei CC; Xu XY; Chen YF; Oparil S; Lucchesi P; Dell'Italia LJ
Circulation; 2001 Feb; 103(7):1012-6. PubMed ID: 11181478
[TBL] [Abstract][Full Text] [Related]
7. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
Agata J; Ura N; Yoshida H; Shinshi Y; Sasaki H; Hyakkoku M; Taniguchi S; Shimamoto K
Hypertens Res; 2006 Nov; 29(11):865-74. PubMed ID: 17345786
[TBL] [Abstract][Full Text] [Related]
8. Additive amelioration of oxidative stress and cardiac function by combined mineralocorticoid and angiotensin receptor blockers in postinfarct failing hearts.
Noda K; Kobara M; Hamada J; Yoshifuji Y; Shiraishi T; Tanaka T; Wang J; Toba H; Nakata T
J Cardiovasc Pharmacol; 2012 Aug; 60(2):140-9. PubMed ID: 22549451
[TBL] [Abstract][Full Text] [Related]
9. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
10. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
[TBL] [Abstract][Full Text] [Related]
11. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
Barr CS; Lang CC; Hanson J; Arnott M; Kennedy N; Struthers AD
Am J Cardiol; 1995 Dec; 76(17):1259-65. PubMed ID: 7503007
[TBL] [Abstract][Full Text] [Related]
12. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotective mechanisms of spironolactone associated with the angiotensin-converting enzyme/epidermal growth factor receptor/extracellular signal-regulated kinases, NAD(P)H oxidase/lectin-like oxidized low-density lipoprotein receptor-1, and Rho-kinase pathways in aldosterone/salt-induced hypertensive rats.
Nakano S; Kobayashi N; Yoshida K; Ohno T; Matsuoka H
Hypertens Res; 2005 Nov; 28(11):925-36. PubMed ID: 16555582
[TBL] [Abstract][Full Text] [Related]
14. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling.
Stas S; Whaley-Connell A; Habibi J; Appesh L; Hayden MR; Karuparthi PR; Qazi M; Morris EM; Cooper SA; Link CD; Stump C; Hay M; Ferrario C; Sowers JR
Endocrinology; 2007 Aug; 148(8):3773-80. PubMed ID: 17494996
[TBL] [Abstract][Full Text] [Related]
15. Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients.
Orea-Tejeda A; Colín-Ramírez E; Castillo-Martínez L; Asensio-Lafuente E; Corzo-León D; González-Toledo R; Rebollar-González V; Narváez-David R; Dorantes-García J
Rev Invest Clin; 2007; 59(2):103-7. PubMed ID: 17633796
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone, but not angiotensin II, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes.
Yamamuro M; Yoshimura M; Nakayama M; Abe K; Sumida H; Sugiyama S; Saito Y; Nakao K; Yasue H; Ogawa H
Circ J; 2008 Aug; 72(8):1346-50. PubMed ID: 18654024
[TBL] [Abstract][Full Text] [Related]
17. Impaired neuronal and vascular responses to angiotensin II in a rabbit congestive heart failure model.
Nap A; Belterman CN; Mathy MJ; Balt JC; Pfaffendorf M; van Zwieten PA
J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):220-7. PubMed ID: 14689369
[TBL] [Abstract][Full Text] [Related]
18. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition.
van de Wal RM; Plokker HW; Lok DJ; Boomsma F; van der Horst FA; van Veldhuisen DJ; van Gilst WH; Voors AA
Int J Cardiol; 2006 Jan; 106(3):367-72. PubMed ID: 16337046
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors.
Ishiyama Y; Gallagher PE; Averill DB; Tallant EA; Brosnihan KB; Ferrario CM
Hypertension; 2004 May; 43(5):970-6. PubMed ID: 15007027
[TBL] [Abstract][Full Text] [Related]
20. Cardiac and renal distribution of ACE and ACE-2 in rats with heart failure.
Cohen-Segev R; Francis B; Abu-Saleh N; Awad H; Lazarovich A; Kabala A; Aronson D; Abassi Z
Acta Histochem; 2014 Oct; 116(8):1342-9. PubMed ID: 25217176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
